WebFeb 6, 2024 · HANGZHOU, China and SHAOXING, China, Feb. 6, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the approval of the Investigational … WebMay 13, 2024 · Ascletis is committed to developing and commercializing antiviral, steatohepatitis, and tumor-related innovative drugs for unmet medical needs in China and Globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain …
Ascletis Presented Positive Phase I Clinical Data for Broad …
WebApr 10, 2024 · Ascletis Pharma’s headquarters are located at Building D 198 Qidi Hipark Xiaoshan District Rd 12TH Fl, Hangzhou, China How do I contact Ascletis Pharma? … WebJan 31, 2024 · Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. hulan and maya james
Ascletis Announces U.S. FDA Approval of Conducting a Phase …
WebMay 16, 2024 · HANGZHOU and SHAOXING, China, May 16, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included … WebNov 17, 2024 · HANGZHOU and SHAOXING, China, Nov. 16, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the approval of the … WebMay 11, 2024 · The U.S. FDA approved ASC22 trial is a multi-center, randomized, single-blind, placebo-controlled, Phase I/II clinical trial to evaluate the safety, efficacy, and pharmacokinetics characteristics... hulan 12 lerum